Bristol Myers turns to Oxford Biomedica for CAR-T manufacturing

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/tadamichi)
(Image: Getty/tadamichi)

Related tags: Bristol Myers Squibb, Bristol-myers squibb, CAR-T

Oxford Biomedica set to receive up to $96m to support the development of Juno’s CAR-T therapies.

The agreement will see Oxford Biomedica partner with Juno Therapeutics, a chimeric antigen receptor (CAR)-T therapy developer, acquired​ in 2018 by Celgene, which is, in turn, now a Bristol Myers Squibb company​.

Under a non-exclusive license, Oxford Biomedica will provide Juno with access to its LentiVector platform, supporting the development of the latter’s CAR-T and T cell receptor therapeutics (TCR-T) programs.

Moreover, the companies have agreed to a five-year long clinical supply of lentiviral vectors for Juno’s development projects, with the potential for further extension of the agreement.

Per the financial terms, Oxford Biomedica will receive an upfront cash payment of $10m (€9.3m); up to $86m (€80.1m) dependent on development and regulatory milestones; and up to $131m (€122.1m) in sales-based milestone payments.

The manufacturing work has begun at Oxford Biomedica's commercial manufacturing center located in Oxford, UK, with the manufacturer working on four undisclosed projects.

Juno and BMS are putting significant efforts​ into optimizing manufacturing for CAR-T development projects, since a potential approval would see any product arrive as the third to market, after the commercialization of Novartis’ Kymriah (tisagenlecleucel), and Gilead’s Yescarta (axicabtagene ciloleucel).

In December 2019, BMS won a patent infringement suit​ against Gilead on Yescarta, which saw the latter’s subsidiary, Kite, ordered to pay Juno $752m – though Juno then requested the judge to raise that penalty to $1.5bn.

Related news

Show more

Related products

show more

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Related suppliers

Follow us

Products

View more

Webinars